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SUMMARY
Objective: Evaluate the seizure-reduction response and safety of brain-responsive
stimulation in adults with medically intractable partial-onset seizures of neocortical
origin.
Methods: Patients with partial seizures of neocortical origin were identified from
prospective clinical trials of a brain-responsive neurostimulator (RNS System, Neuro-
Pace). The seizure reduction over years 2–6 postimplantation was calculated by assess-
ing the seizure frequency compared to a preimplantation baseline. Safety was assessed
based on reported adverse events. Additional analyses considered safety and seizure
reduction according to lobe and functional area (e.g., eloquent cortex) of seizure onset.
Results: There were 126 patients with seizures of neocortical onset. The average follow-
up was 6.1 implant years. The median percent seizure reduction was 70% in patients with
frontal and parietal seizure onsets, 58% in those with temporal neocortical onsets, and 51%
in those with multilobar onsets (last observation carried forward [LOCF] analysis).
Twenty-six percent of patients experienced at least one seizure-free period of 6 months or
longer and 14% experienced at least one seizure-free period of 1 year or longer. Patients
with lesions on magnetic resonance imaging (MRI; 77% reduction, LOCF) and those with
normal MRI findings (45% reduction, LOCF) benefitted, although the treatment response
was more robust in patients with an MRI lesion (p = 0.02, generalized estimating equation
[GEE]). There were no differences in the seizure reduction in patients with and without
prior epilepsy surgery or vagus nerve stimulation. Stimulation parameters used for treat-
ment did not cause acute or chronic neurologic deficits, even in eloquent cortical areas.
The rates of infection (0.017 per patient implant year) and perioperative hemorrhage
(0.8%) were not greater than with other neurostimulation devices.
Significance: Brain-responsive stimulation represents a safe and effective treatment
option for patients with medically intractable epilepsy, including adults with seizures
of neocortical onset, and those with onsets from eloquent cortex.
KEY WORDS: Closed-loop, Neuromodulation, Partial seizures, Eloquent cortex,
Brain stimulation.
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Seizure outcomes after focal neocortical resection vary
depending on whether there is a lesion corresponding to the
seizure onset(s).1 In studies of adults, 53% of patients with a
lesion corresponding to the seizure focus were seizure-free
after a focal cortical resection, whereas if there was no
lesion, only 26% of patients achieved seizure freedom.2
Whether or not a lesion is identified, patients with seizures
arising from eloquent cortex are at risk for neurologic defi-
cits. Depending on the area of brain resected, 17–67% of
patients who undergo focal cortical resection of extratempo-
ral areas report new or increased neurologic deficits after
surgery.3–8 Patients who are not good candidates for cortical
resection because of risk to neurologic function—such as
patients with seizure onsets in eloquent cortex—may con-
sider brain-responsive stimulation as a therapeutic option.
The RNS System (NeuroPace, Mountain View, CA,
U.S.A.) is the only brain-responsive neurostimulator
approved by the U.S. Food and Drug Administration (FDA)
as an adjunctive therapy in reducing the frequency of sei-
zures in individuals with partial-onset seizures who are
≥18 years of age, with ≤2 epileptogenic foci, and who are
refractory to ≥2 antiepileptic medications.9,10 The
randomized controlled trial leading to FDA approval
demonstrated a significantly greater seizure reduction in
patients treated with brain-responsive neurostimulation
compared to sham-stimulated patients, with no significant
differences in adverse event rates between the two groups.9
The median percent seizure reduction in the open-arm
extension was 44% at 1 year and 53% at 2 years,11 and ran-
ged from 48% to 66% in years 3–6 in a long-term open-label
study.10 To obtain information about safety and seizure
reduction in patients with neocortical seizure foci being
treated with brain-responsive stimulation, outcomes were
assessed in this subset of patients in the clinical trials of the
RNS System, with an additional focus on responses of
patients treated in eloquent cortex.
Methods
The RNS System is a closed-loop, brain-responsive neu-
rostimulator. A cranially implanted neurostimulator is con-
nected to depth and/or cortical strip leads that are placed at
one or two previously localized seizure foci. Each lead con-
tains four electrode contacts. Two leads can be connected to
the neurostimulator at a time, and up to four leads were
implanted during the clinical trials. The neurostimulator
continually senses electrocorticographic (ECoG) activity
through the electrodes. It is programmed by the physician to
detect patient-specific ECoG patterns and deliver brief stim-
ulation pulses through the electrodes in response. Physicians
adjust detection and stimulation parameters as needed.
Patients in this series had seizures localized to one or two
foci in the neocortex. Patients were categorized by lobe of
seizure onset based on case report form (CRF) data derived
from the presurgical evaluation. Lead placement was deter-
mined by CRF or by visual inspection of postoperative
imaging. Additional analyses were performed in those sub-
sets of patients with onsets in eloquent cortex and insula.
Patients with seizures of frontal onset were included in the
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Key Points
• Responsive stimulation is a well-tolerated treatment
option for patients with onsets in neocortical areas,
including eloquent cortex
• Median seizure reductions were 58% using a LOCF
analysis
• Twenty-six percent of patients experienced at least one
seizure-free period ≥6 months and 14% experienced at
least one seizure-free period ≥1 year
• Both patients with lesions and those with normal MRIs
benefitted, although the treatment response was more
robust in patients with a lesion
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primary motor group if leads spanned the primary motor
cortex and the patient had simple partial motor seizures at
baseline. Patients with frontal-onset seizures with leads
in Broca’s area were identified, as were patients with
leads spanning the left superior posterior temporal gyrus
(Wernicke’s area). Common lead placement strategies
are depicted in Figure 1. All patients provided written
informed consent. The studies were registered on
A
B C
D
Figure 1.
Lead placement strategies. Patient A
had simple partial seizures
characterized by left-sided tingling
and/or weakness followed by bilateral
motor signs. Two leads were placed
over the right frontal lobe in the
interhemispheric space (red arrows)
and two leads spanning the superior
aspect of the right lateral frontal lobe
(green arrows). The superior
interhemispheric lead and the
posterior lateral lead were
connected to the neurostimulator.
Patient B had complex partial
seizures characterized by pressure
and butterflies in the stomach
followed by vocalization and loss of
balance. Three leads were placed
over the parietal lobe in the
interhemispheric space (red arrows),
and an additional lead was placed on
the right lateral parietal cortex (green
arrow). The anterior and posterior
superior interhemispheric leads were
connected to the neurostimulator.
Patient C had generalized tonic–
clonic seizures in addition to simple
and complex partial seizures
characterized by a loss of hearing.
Three cortical strip leads were placed
over the left posterior temporal lobe.
Patient D had simple partial seizures
with motor signs on the right as well
as complex partial seizures with loss
of awareness. Two depth leads were
targeted at the anterior and posterior
left insular cortex and two cortical
strip leads were placed over the left
frontal and anterior parietal cortices
(green arrows). The posterior insular
lead and frontal strip lead were
connected to the neurostimulator.©
2017 NeuroPace, Inc.
Epilepsia ILAE
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www.clinicaltrials.gov (NCT00079781, NCT00264810,
and NCT00572195).
For subset analyses of seizure reduction by region of
onset, only patients who received stimulation in the brain
region of interest and had seizure frequency data in the
open-label period were included. To control for possible
effects of patient withdrawal, last observation carried for-
ward (LOCF) analyses were performed using the most
recent 3 months of data (84 days) available for that patient
before the data cutoff (November 1, 2014). To examine the
response over time, the median percent change in seizures
was calculated for each 3-month period during which sei-
zure data were available. Missing days of seizure diary data
were not imputed as seizure-free.
Generalized estimating equations (GEEs) were used to
determine whether changes in response to treatment varied
according to demographic characteristics. GEEs are an
extension of generalized linear modeling that handle miss-
ing data and properly assign significance to multiple corre-
lated measurements.12 The percent change in seizure rate
for all available 3-month epochs during the open-label per-
iod was analyzed using a GEEmodel with a compound sym-
metric correlation structure. p-Values are based on
empirical standard errors.
Adverse event (AE) and daily patient-reported seizure
diary data were collected every 6 months. Adverse events
were adjudicated by the physician as device related, of
uncertain device relation, or not device related. Serious
adverse events were defined as those requiring hospital-
ization. An independent Data Monitoring Committee
reviewed all AEs and a second committee determined
whether deaths met criteria for Sudden Unexpected Death
in Epilepsy (SUDEP). All study protocols were approved
by the institutional review boards of participating investi-
gational sites.
Results
One hundred twenty-six patients in the RNS System trials
were identified as having seizures of neocortical origin. This
pool of patients included patients from the RNS System
Feasibility (n = 45) and Pivotal Trials (n = 81). Patients
were followed for an average of 6.1  2.6 patient implant
years with an accumulated experience of 774 patient
implant years and 719 stimulation years. Patient account-
ability is shown in S1. Demographic characteristics of these
patients are presented in Table 1.
Stimulation was delivered at current amplitudes that var-
ied from 0.5 mA to 12.0 mA. The most common settings
were 3.0 mA, followed by 6.0 and 12.0 mA. Stimulation
frequency was usually set at 100 or 200 Hz, pulse width at
160 ls, and burst duration at 100 msec. The most common
charge density delivered was 6.1 lC/cm2. The median num-
ber of stimulations delivered per day was 799 (range:
2–3,167), resulting in <10 min of stimulation delivered per
day at standard settings. The number of stimulations per day
was similar for patients with and without dysplasia.
Seizure reduction
Of the 126 patients with seizures of neocortical onset,
122 had seizure frequency data during the open label-per-
iod. Of these, 120 patients had >1 year of follow-up, and
87 had at least 6 years of follow-up. There was a reduc-
tion in seizures with treatment with the RNS System that
continued to improve with time. The median percent
reduction in seizures at the end of year 2 was 44%, and
over years 5 and 6 ranged from 61% to 76% (Fig. 2). The
improvement was not due to patient withdrawals; an
LOCF analysis showed a median percent change of
58% (interquartile range [IQR] 11% to 95%) and a
responder rate of 55% (95% confidence interval [CI] 46–
63%). Some patients had prolonged periods of seizure
freedom. During the open-label period, 37% of patients
had at least one seizure-free interval lasting ≥3 months,
26% had at least one lasting ≥6 months, and 14% had at
least one lasting ≥1 year.
Seizure reductions were analyzed by demographic char-
acteristic (Table 2). Seizure reductions were not different in
Table 1. Baseline and demographic characteristics of
patients in the RNS system trials with seizure onsets of
neocortical origin
Characteristic Mean SD (min-max) or % (n)
Age (years) 30.4  10.1 (18–63)
Female 50% (63)
Duration of epilepsy (years) 19.5  10.2 (4–47)
Number of AEDs at enrollment 3.1  1.1 (1–6)
Baseline seizure frequency
(disabling seizures/month)
88.0  246.7 (0a–2,320)
median = 20.0
Seizure onset
Frontal 31% (39)
Parietal 13% (17)
Temporal 25% (32)
Occipital 3% (4)
Multilobar 27% (34)
Lesion on imaging 55% (69)
Dysplasia 29% (37)
Other 25% (32)
Number of seizure
foci – two (vs. one)
26% (33)
Prior therapeutic
surgery for epilepsyb
52% (65)
Prior EEGmonitoring with
intracranial electrodesc
82% (103)
Prior VNS 37% (46)
(N = 126).AED, antiepileptic drug; EEG, electroencephalogram; VNS,
vagus nerve stimulator.
aOne patient in the Feasibility Trial had only simple partial sensory seizures
during the 3-month baseline.
bResection only (n = 52); subpial transection only (n = 5); callosotomy
only (n = 2); Resection + Subpial transection (n = 4); Resection + Calloso-
tomy (n = 2).
c17/23 patients who did not have intracranial monitoring had a lesion on
neuroimaging.
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patients who had been treated with a previous epilepsy sur-
gery compared to those who had not (p = 0.12), and in those
treated previously with vagus nerve stimulation (VNS) and
those who had not (p = 0.20). There were also no signifi-
cant differences that could be attributed to having had
intracranial monitoring to localize the seizure focus
(p = 0.08). It should be noted that the majority of patients
(82%, 103/126) underwent intracranial monitoring to local-
ize the seizure focus, and most patients who did not do so
had a structural lesion (74%, 17/23). Both patients with and
without structural lesions experienced a reduction in seizure
frequency. The reduction was greater in patients with a
structural lesion (77%, LOCF) than in those without one
(45%, LOCF), and the difference between these groups was
significant over the entire follow-up (p = 0.02, GEE).
Safety
There were nine serious adverse events related to
intracranial hemorrhage. In six of the nine patients, hemor-
rhages were attributed to seizure-related head trauma
(4.8%). Of the three patients who had non–seizure-related
hemorrhages, one patient (0.8%) had a perioperative subdu-
ral hematoma that was evacuated with no neurologic conse-
quences. Two patients (1.6%) had cerebral hemorrhages
several years after implantation. One was considered device
related, and the patient had transient arm and hand weakness
Figure 2.
Median percent change in disabling seizures during the open label period. Observed median percent seizure reduction in 3-month epochs
over the duration of follow-up (years 2–6). Blue: All Neocortical; Green: Frontal; Red: Temporal; Teal: Multilobar. The study is ongoing
and not all patients have completed all 7 years; therefore, the number of patients decreases over time. Aggregated data are presented for
groups with at least 20 patients. Responses for smaller groups (i.e., parietal, occipital, and eloquent cortical areas) are presented in
Table 3. IQR, interquartile range, 25th to 75th percentile.© 2017 NeuroPace, Inc.
Epilepsia ILAE
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and ultimately had the neurostimulator and leads explanted.
The second cerebral hemorrhage was considered to be of
uncertain device relation; the patient was hospitalized with
severe headache. An intracranial hemorrhage over the tem-
poral lobe and signs of vasospasm were noted on imaging.
The event resolved and the patient continued to be treated
with the RNS System.
There were 13 serious AEs related to infection in 13
patients over 774 patient implant years, for a rate of 0.017
infections per patient implant year. One of these infections
was attributed to a scalp abrasion sustained during a seizure.
Nine of the 13 patients had the neurostimulator explanted
and 6 had leads removed as well. Two of these patients were
later re-implanted with a neurostimulator. One of the two
patients developed an osteomyelitis that was classified by
the investigator as of uncertain device relation. This patient
had multiple procedures in the week after the explant,
including implantation of subdural grids, resection of pre-
motor cortex, and reimplantation of a neurostimulator and
cortical strip leads. The infection, which was noted 6 days
after the resection, resolved and the wound healed well.
There were no instances of treatment emergent meningitis
or brain parenchyma infections.
Two patients (1.6%) developed scalp erosions over the
neurostimulator. One of these patients had two erosions.
The neurostimulator in this patient was placed in a partial
thickness craniotomy so that the neurostimulator lay above
the skull, rather than the flush profile achieved with a full-
thickness craniotomy.
There were five deaths: one by suicide in a patient with a
history of depression who was not being treated with
responsive stimulation at the time of the event, one due to
status epilepticus in a patient whose levels of antiepileptic
medications were subtherapeutic, one due to lymphoma,
and two that were attributed to definite SUDEP.
The only serious AEs (device-related or of uncertain
device relation) that occurred in ≥5.0% of patients were
implant-site infection (discussed above) and premature bat-
tery depletion, which occurred in eight patients (6.3%). All of
these events occurred with a battery made by a manufacturer
that is no longer in use. No patient had seizure-related adverse
events with initiation of stimulation and no patient withdrew
from the study due to a seizure-related adverse event.
Outcomes by lobe of seizure onset
The LOCF percent change and responder rates for
patients by lobe of onset and for areas of eloquent cortex are
shown in Table 3, and the median percent change in sei-
zures over time by lobe of onset is shown in Figure 2.
Brain-responsive stimulation was effective at reducing sei-
zures in all lobes of the neocortex. Examples of the electro-
graphic seizure onsets by lobe of onset recorded by the RNS
System are provided in Figure 3. There were no mild or
serious device-related AEs such as involuntary motor activ-
ity in frontal patients when leads were placed over primary
motor cortex. The patients receiving stimulation in either
Broca’s area or Wernicke’s area did not have any device-
Table 2. Seizure reduction according to demographic
characteristics, LOCF analysis.
Characteristic N
Median % change Responder rate
(IQR) (95%CI)
Prior intracranial
monitoring
Yes 99 58% 54%
(6% to96%) (44% to 63%)
No 23 57% 61%
(32% to83%) (41% to 78%)
Lesion on
neuroimaging
Yes 67 77% 61%
(27% to100%) (49% to 72%)
No 55 45% 47%
(1% to82%) (35% to 60%)
Prior therapeutic
epilepsy surgery
Yes 62 54% 53%
(15% to92%) (41% to 65%)
No 60 62% 57%
(10% to96%) (44% to 68%)
Prior VNS Yes 44 50% 50%
(8% to90%) (36% to 64%)
No 78 62% 58%
(27% to99%) (47% to 68%)
LOCF, last observation carried forward; IQR, interquartile range, 25th to
75th percentile; VNS, vagus nerve stimulator.
Table 3. Seizure reduction by lobe of onset and
functional area.
N
[Individual LOCF change in seizures]
or
LOCF median
% change (IQR)
LOCF
responder
rate (95% CI)
By lobe of onset
Frontala 37 70% 54%
(14% to95%) (38% to 69%)
Parietal 12 70% 58%
(25% to93%) (32% to 81%)
Temporal 27 58% 67%
(38% to97%) (48% to 81%)
Occipital 4 [100%,100%,38%,4%]
Multilobar 33 51% 52%
(7% to91%) (35% to 67%)
By functional
Primary motorb 17 83% 65%
(43% to95%) (41% to 83%)
Broca’sb 2 [100%,91%]
Wernicke’sc 5 [78%,54%,45%,8%, 56%]
Primary visuald 3 [100%,38%,4%]
LOCF, last observation carried forward (most recent 3 months); IQR,
interquartile range, 25th to 75th percentile.
aChange in seizures for the 8 patients with frontal onsets and interhemi-
spheric lead placement was [100%, 95%, 89%, 40%, 23%, 3%, 1%,
65%].
bA subset of the 37 patients with seizures of frontal onset. An individual
patient can be in more than one subset (e.g., data from a patient with a lead in
primary motor cortex and one in Broca’s area will be in both groups).
cA subset of the 27 patients with seizure onset(s) in non-mesial temporal
areas.
dA subset of the 4 patients with seizure onset(s) in the occipital lobe.
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related mild or serious AEs related to language or speech.
One patient with occipital leads reported a transient experi-
ence of brief star-like events (mild) that resolved when the
stimulation current was decreased. Two of the patients who
were classified as having frontal onsets and two as having
multilobar onsets had at least one lead targeted to the insular
cortex. The LOCF seizure changes for these patients were
98%,96%,92%, and 10%. There were no mild or seri-
ous adverse events related to autonomic function in any of
the patients receiving stimulation in the insula.
Discussion
This study provides extensive data on patients with medi-
cally intractable partial seizures arising from neocortex that
were treated with brain-responsive stimulation. There were
acute and long-term improvements in seizure control, and
the stimulation parameters necessary to achieve meaningful
seizure reduction did not cause repeated or sustained defi-
cits in neurologic function in any lobe of the neocortex.
There were no serious AEs related to stimulation of elo-
quent cortex. Rates of infection were well within the
expected range for implantation of intracranial electrodes
for localization of the seizure focus for epilepsy resective
surgery13–17 and for implantation of a deep brain stimulator
for movement disorders18 or for epilepsy.19
Patients who had been treated previously with surgical
resection or VNS were as likely to do well as patients who
had not. The preponderance of patients in this series had
intracranial monitoring for localization of the seizure focus,
and there was no difference in seizure reduction between
patients who did and did not have this monitoring. Of note,
the majority of patients who did not have intracranial moni-
toring had a lesion on imaging. The very small number of
nonlesional patients who did not have intracranial monitor-
ing precludes drawing meaningful conclusions about the
benefits of intracranial monitoring in this series.20
The only demographic characteristic that identified
patients who were more likely to respond was the presence
of structural lesion on magnetic resonance imaging (MRI).
Although both lesional and nonlesional patients benefited
from responsive therapy, seizure reduction was greater in
patients who had a structural lesion. Similarly, studies of
surgical outcomes in patients with focal-onset seizures have
also reported better outcomes in patients who have a lesion
corresponding to the seizure focus than in those who have
nonlesional epilepsy.2,21–23 It is possible that localization of
the seizure focus was less precise in patients without a struc-
tural lesion. However, these patients still had a 45% reduc-
tion in seizures. Because brain-responsive neurostimulation
is a nondestructive therapy, the risk of cognitive or func-
tional deficits for patients without a lesion remains low,
which indicates a favorable risk–reward profile for this
population.
Although some patients can achieve seizure freedom with
cortical resections,24–27 in many instances, a full resection of
Figure 3.
Examples of seizure by lobe of onset.
These examples of electrographic
seizures were recorded by the RNS
System during the prestimulation
baseline in patients with a lead in/
over: (A) right frontal motor cortex;
(B) left lateral temporal lobe; (C)
right parietal lobe; and (D) left lateral
occipital lobe. Spectrograms plot the
power of the ECoG signal at given
frequencies over time (top panel) and
time series data for the ECoG are
shown below each spectrogram.©
2017 NeuroPace, Inc.
Epilepsia ILAE
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the epileptogenic onset zone is not possible because of the
risk of functional deficits. For example, in one series,
although 31% of patients who had resections in motor areas
were seizure-free, 23% had new, severe postoperative defi-
cits.5 Another series reported that 57% of patients with pari-
etal onsets achieved seizure freedom but 30% developed
Gerstmann syndrome.6 A report of patients undergoing
resections of occipital lobe seizure foci found that 71% were
seizure-free, but 39% reported new visual field defects.28
Although treatment with brain-responsive neurostimulation
is less likely to result in seizure freedom than treatment with
epilepsy surgery, substantial seizure reductions were
achieved and several patients achieved extended periods
without seizures. Baseline assessments for the RNS System
trials were limited to 3 months, and thus whether a patient
had a prior history of extended periods of seizure freedom is
unknown. However, patients entering the trials were required
to have uncontrolled seizures at the time of enrollment. In
addition, many of these patients had failed to achieve seizure
control not only with medications, but also with prior resec-
tions and VNS. The seizure reductions achieved with brain-
responsive stimulation did not occur at the expense of cogni-
tive or neurologic function. Furthermore, patients treated
with brain-responsive stimulation in eloquent cortex did not
have implant- or stimulation-related functional deficits.
In fact, Loring et al.,29 reported that patients with neocor-
tical onsets who participated in the Pivotal trial (n = 76)
demonstrated statistically significant improvements in nam-
ing, with 32% meeting criteria for reliable change.29 These
patients also showed statistically significant improvements
in visual memory and executive function. Likewise, they
reported improvements in all domains of quality of life (epi-
lepsy-targeted, cognitive, mental health, and physical
health), and 51% reported clinically meaningful improve-
ments in overall quality of life.30
There are limitations to this analysis of open-label data
from the RNS System trials. The trials were not powered to
provide an estimate of the effect size (i.e., seizure reduction)
in subsets of patients, as evidenced by the relatively large
IQR. More data are needed to accurately estimate effect
size. Whether a patient was categorized as having a struc-
tural lesion was based on physician report, rather than on a
standardized MRI protocol or histopathology. Based on the
data collected in the clinical trials, it is not possible to know
whether changes in any one antiepileptic drug (AED)
affected seizure outcomes, since investigators in the trial
were able to adjust AEDs as needed for management of their
patients’ epilepsy. However, previously published data that
includes data from the patients in this series indicate that
seizure response in patients whose AEDs remained stable
was similar to that of patients who had AEDs added or
decreased.11
An additional limitation to the current analysis is that, as
with all new epilepsy therapies, the outcomes of the RNS
System clinical trials were dependent on patient-reported
seizure diary data. Recent studies conducted in the epilepsy
monitoring unit have indicated that patients are not aware of
>50% of their complex partial and secondarily generalized
tonic–clonic seizures.31,32 Although the seizure diary
remains the gold standard for epilepsy trials and seizure
diary estimates of seizure frequency have been found to be
consistent across time,33 an objective measure of disease
frequency and severity would be beneficial, and analyses of
the RNS System data are underway.
It could be that the patients who did not respond to stimu-
lation therapy did not have optimal lead placement or stimu-
lation settings. It is not known whether stimulation needs to
be delivered directly at the seizure focus,34 near the focus,
or in relevant propagation pathways or networks. In addi-
tion, although patients with MRI-identified lesions tended
to respond well to stimulation, it is uncertain from the cur-
rent study how the type and volume of a lesion may impact
outcome. Additional clinical data will be necessary to pro-
vide the opportunity to assess whether MRI and functional
neuroimaging studies such as magnetoencephalography
(MEG), single-photon emission tomography (SPECT), and
positron emission tomography (PET) can help refine patient
selection and guide lead placement to improve efficacy. In
the future, alternative stimulation strategies, such as low-
frequency stimulation and longer duration pulses can be
evaluated to increase efficacy in those patients who do not
respond to high-frequency, short-burst stimulation.35 More-
over, understanding the volume of tissue activated by the
different stimulation approaches may help guide the person-
alization of the therapy for individual patients.
One third of patients with partial-onset seizures do not
respond optimally to medications, and although many are
candidates for focal cortical resections,15 results of surgery
in patients with seizures arising from neocortical areas are
less encouraging than those in patients with seizures origi-
nating from the mesial temporal lobe.36,37 One possible
explanation for this is that a neocortical epileptic focus is
more difficult to localize than a mesial temporal seizure
focus. Another reason for surgical failure is that a full resec-
tion of the seizure focus may not be possible because of the
risk of functional deficit.38 Nondestructive therapies such as
responsive neurostimulation may be an option for these
patients. The benefit of responsive stimulation in patients
with seizure onsets in the neocortex is achieved with stimu-
lation settings that are below the perceptual threshold in
almost every case. In addition, there are no known chronic
stimulation-related side effects. This experience supports
brain-responsive neurostimulation as a treatment option for
adults with partial-onset seizures arising from any region of
the neocortex, including eloquent cortex.
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